Loading…
← CockpitCompetitor Analysis › LBRX LB Pharmaceuticals, Inc.Open in the cockpit ↗

LB Pharmaceuticals, Inc.LBRXCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Clinical-stage biotech developing LB-102, an oral antipsychotic drug candidate for schizophrenia.

Momentum strong 73
Mkt cap
$1.30B
US dollars, full cap
Free float
74%
of shares outstanding
$/day
$14.8M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 9.2%
Hurdle
n/a
no reverse DCF
Next earnings
134 days
1 Apr 2027
Close · USD$40.06
1D-0.6%
1W-10.4%
1M-2.3%
3M-15.2%
6M+42.9%
YTD+80.0%
1Y+135.0%
ATR %6.8%
Beta0.89
52w lowhigh20.1% off high

What LB Pharmaceuticals does

Clinical-stage biotech developing LB-102, an oral antipsychotic drug candidate for schizophrenia.

Has no product revenue and pays for trials by selling shares, so each trial result affects how much capital it can raise. LB-102 is a modified form of amisulpride, an antipsychotic sold in Europe but never approved in the US, which gives it a safety record from abroad.

Products and services

  • LB-102 (schizophrenia)

Where it sits in the supply chain

  • Biopharma R&D
  • CNS/antipsychotic drug development
  • Schizophrenia clinical trials

What could go right

  • Positive pivotal trial data
  • Differentiated side-effect profile vs older antipsychotics

What could go wrong

  • Crowded, largely generic antipsychotic market
  • Binary late-stage trial risk

Moat: none (IP / patents). Pre-commercial; competes in a crowded antipsychotic market against established generics and branded drugs.

Headquarters: New York, New York, US · Founded: 2019 · Employees: 27

Named competitors

LB Pharmaceuticals at a glance

Size LB Pharmaceuticals (LBRX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.30B, the 2074th largest of 3,085 United States companies the cockpit tracks. Shares closed at $40.06 on 18 Nov 2026.

Performance Over six months the shares gained 42.9%, against -17.3% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 20 in its peer set.

Short interest Short interest is 19.1% of the free float (30 Oct 2026).

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026LBRX 143Peer median 84
Six months, rebased to 100: LB Pharmaceuticals against the median of its 20 peers (local-currency closes).

LB Pharmaceuticals financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$388,000-$321,000-$91,000-$4,000-$2,000
EBITDA-$152M-$30.1M-$64.7M-$11.4M-$2.81M
Net income-$141M-$25.2M-$63.1M-$6.28M-$14.3M
Free cash flow-$144M-$35.3M-$53.8M-$12.1M-$2.73M
Capital expenditure$505,000$52,000$769,000$25,000$0
Total debt$5.16M$3.57M$3.70M$0$24.1M

Quarterly statements and history in the cockpit →

LB Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%301263OCULINVAMNKD002332688293068760AMPH002099300204300181NANO226950GPCRAVLN300026LBRX6-month return →1-month return →
Up and to the right = strong over both horizons. LB Pharmaceuticals is the large dot.

LB Pharmaceuticals competitors and peer comparison

Head to head with its named competitors (LBRX vs BMY vs ABBV vs ALKS)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
LB Pharmaceuticals LBRX$1.30B+43%n/an/an/an/a
Bristol Myers Squibb BMY$122B+3%+4%33%3.1×-13.1%
AbbVie ABBV$506B+35%+11%36%8.7×-0.1%
Alkermes Public ALKS$7.87B+27%+15%5%5.0×32.5%

How LB Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

LB Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureLBRXPeer medianRank in peer set
1-month return-2.3%-4.8%8th highest of 20
6-month return+42.9%-17.3%2nd highest of 20
Distance from 52-week high-20.1%-37.5%3rd highest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
LB Pharmaceuticals LBRXUnited States$1.30B+43%n/an/an/an/an/a
Guangdong Taienkang Pharmaceutical 301263.SZChina$1.30B-24%+2%-2%12.8×n/an/a
Ocular Therapeutix OCULUnited States$1.31B-26%-10%-681%17.0×n/an/a
Innoviva INVAUnited States$1.31B-17%+12%38%2.2×-17.2%+3.9%
MannKind MNKDUnited States$1.31B+25%+32%-2%4.0×n/an/a
Windward Bio WWBUnited States$1.31Bn/an/an/an/an/an/a
Zhejiang Xianju Pharmaceutical 002332.SZChina$1.28B-1%+8%11%2.0×-0.4%-1.3%
Shanghai OPM Biosciences 688293.SSChina$1.32B+36%+133%11%9.6×25.9%+23.1%
Celltrion Pharm 068760.KSSouth Korea$1.33B-23%+16%12%3.0×10.2%+18.1%
Amphastar Pharmaceuticals AMPHUnited States$1.27B+64%+3%19%2.3×2.5%+15.5%
Zhejiang Hisoar Pharmaceutical 002099.SZChina$1.33B-2%+9%-13%4.7×n/an/a
Staidson (Beijing) Biopharmaceuticals 300204.SZChina$1.26B-41%-24%-51%39.1×n/an/a
GH Research GHRSUnited States$1.25B-19%n/an/an/an/an/a
Zhejiang Jolly Pharmaceutical 300181.SZChina$1.34B-15%+17%20%3.0×3.9%+22.8%
Sinopep-Allsino Bio Pharmaceutical 688076.SSChina$1.25B-16%+14%19%4.8×3.4%+27.9%
Nanobiotix NANO.PAFrance$1.35B-32%-77%-392%146.3×n/an/a
C.Q. Pharmaceutical 000950.SZChina$1.24B-27%-3%1%0.5×n/an/a
OliX Pharmaceuticals 226950.KSSouth Korea$1.35B-51%+27%-384%125.0×n/an/a
Structure Therapeutics, Inc. Sponsored ADR GPCRUnited States$1.24B-53%n/an/an/an/an/a
Avalyn Pharma AVLNUnited States$1.23B-1%n/an/an/an/an/a
Tianjin Chase Sun Pharmaceutical 300026.SZChina$1.23B-10%-29%3%1.8×7.0%-5.3%

Questions

Who are LB Pharmaceuticals's main competitors?
Named competitors: Bristol Myers Squibb (Karuna) (BMY), AbbVie (Cerevel) (ABBV), Alkermes (ALKS). The cockpit's measured peer set (industry) also includes Guangdong Taienkang Pharmaceutical (301263.SZ), Ocular Therapeutix (OCUL), Innoviva (INVA), MannKind (MNKD), Windward Bio (WWB), Zhejiang Xianju Pharmaceutical (002332.SZ).
How has LB Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned +42.9% against -17.3% for the median peer; over one year +135.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.